• Medicine
  • Published in
    American journal of cancer…
    2015

BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.

@article{Wang2015BCL6IA,
  title={BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.},
  author={Yi-Qin Wang and Mi-die Xu and Wei-wei Weng and Ping Wei and Yu-si Yang and Xiang Du},
  journal={American journal of cancer research},
  year={2015},
  volume={5 1},
  pages={
          255-66
        }
}
BACKGROUND Dysregulation of BCL6 plays critical oncogenic roles and facilitates tumorigenesis in various malignancies. However, whether the aberrant expression of BCL6 in ovarian carcinoma is associated with malignancy, metastasis or prognosis remains unknown. Our study aimed to investigate the expression of BCL6 in ovarian carcinoma and its possible correlation with clinicopathological features as well as patient survival to reveal its biological effects in ovarian tumor progression. METHODS… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Synthesis and Antiproliferative Activity of Hybrid Peptides for Ovarian and Prostate Cancer

VIEW 1 EXCERPT
CITES BACKGROUND

High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer

  • Liancheng Zhu, Huilin Feng, +7 authors Bei Lin
  • Biology, Medicine
  • Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • 2017

APPLICATION OF GRAPH MODELS IN BIOINFORMATICS

VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.

  • Yiru Wang, Binwei Yao, +6 authors Jie Tang
  • Medicine, Biology
  • International journal of molecular medicine
  • 2014
VIEW 2 EXCERPTS